Parabilis Medicines, Inc. (PBLS) Income Statement
PBLS 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsPBLS revenue and net income
PBLS growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
PBLS quarterly EPS vs estimates
Parabilis Medicines beat the analyst EPS estimate in 0 of the last 1 quarters. Next report: November 12, 2026 (estimate $-0.45).
PBLS income statement
| 2025 | 2024 | |
|---|---|---|
| Revenue | $0 | $0 |
| Research & development | $125.6M | $100.8M |
| Sales, general & admin | $26.5M | $25.3M |
| Total operating expenses | $152.1M | $126.1M |
| Operating income | −$152.1M | −$126.1M |
| Interest income | $3.4M | $6.4M |
| Interest expense | $1.5M | $1.5M |
| Income before taxes | −$145.9M | −$117.9M |
| Net income | −$145.9M | −$117.9M |
| EBITDA | −$141.9M | −$114.3M |
| EPS (diluted) | −$72.25 | — |
| Jun '26 | Mar '26 | Jun '25 | Mar '25 | |
|---|---|---|---|---|
| Revenue | $148,000 | $0 | $0 | $0 |
| Cost of revenue | $0 | — | $618,000 | — |
| Gross profit | $148,000 | — | −$618,000 | — |
| Research & development | $39.4M | $37.8M | $30.1M | $33.9M |
| Sales, general & admin | $11.7M | $9.7M | $6.4M | $6.3M |
| Total operating expenses | $51.0M | $47.5M | $35.9M | $40.2M |
| Operating income | −$50.9M | −$47.5M | −$36.5M | −$40.2M |
| Interest income | $4.2M | $2.4M | $1.0M | $1.3M |
| Interest expense | $210,000 | $292,000 | $396,000 | $399,000 |
| Income before taxes | −$52.5M | −$45.3M | −$34.8M | −$38.3M |
| Net income | −$52.5M | −$45.3M | −$34.8M | −$38.3M |
| EBITDA | −$51.7M | −$44.4M | −$35.9M | −$37.3M |
| EPS (diluted) | −$2.13 | — | — | — |
| Gross margin | 100.0% | — | — | — |
| Operating margin | −34,382.4% | — | — | — |
| Net margin | −35,448.0% | — | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in PBLS's financial statements (latest annual report filed December 31, 2025); data from EODHD. Sales, general & administrative expenses include sales and marketing.
PBLS financial results
Parabilis Medicines reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $145.9 million. Diluted earnings per share came to −$72.25.
See the PBLS stock overview for the latest quote and news, or the PBLS chart for price history and technical indicators.
PBLS income statement FAQ
Does Parabilis Medicines have revenue?
Parabilis Medicines reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Parabilis Medicines profitable?
No. Parabilis Medicines reported a net loss of $145.9 million in fiscal 2025.
How much does Parabilis Medicines spend on research and development?
Parabilis Medicines spent $125.6 million on research and development in fiscal 2025.
What are Parabilis Medicines's earnings per share?
Parabilis Medicines earned $-72.25 per diluted share in fiscal 2025.
When will Parabilis Medicines report its next earnings?
Parabilis Medicines is expected to report results for the quarter ending September 30, 2026 on November 12, 2026 before the market opens.
When does Parabilis Medicines's fiscal year end?
Parabilis Medicines's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on December 31, 2025.